['non-small cell lung cancer']
['nivolumab', 'docetaxel']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Disease progression experienced during or after one prior platinum containing doublet
             chemotherapy

          -  Stage IIIb/IV or recurrent disease

          -  Male and Female ≥ 18 years of age

          -  Measurable disease per RECIST 1.1

          -  Performance Status ≤ 1

        Exclusion Criteria:

          -  History of Carcinomatous meningitis

          -  Active Central nervous system (CNS) metastases

          -  History of auto immune diseases

          -  Prior treatment with Docetaxel

          -  Prior treatment with ipilimumab or any drug targeting T-Cell costimulation or
             checkpoint pathways
      